Paclitaxel chemotherapy treatment often leads to neuropathic pain resistant to available
analgesic treatments. Recently spinal Toll-like receptor 4 (TLR4) and the transient receptor …

Chemotherapy-induced peripheral neuropathy is a serious adverse effect of
chemotherapeutic agents such as paclitaxel. JTC-801, a nociceptin/orphanin FQ opioid …

Paclitaxel chemotherapy is limited by a long-lasting painful neuropathy that lacks an
effective therapy. In this study, we tested the hypothesis that paclitaxel may release mast cell …

The clinical use of the antineoplastic agent paclitaxel (Taxol) is significantly limited in its
effectiveness by a dose-related painful peripheral neuropathy. To evaluate underlying …

As one of the most effective and frequently used chemotherapeutic agents, paclitaxel
produces peripheral neuropathy (paclitaxel-induced peripheral neuropathy or PIPN) that …

Background: Paclitaxel is an effective chemotherapeutic agent widely used for the treatment
of solid tumors. The major dose-limiting toxicity of paclitaxel is peripheral neuropathy. The …

Paclitaxel is a chemotherapeutic agent used to treat solid tumours. However, it causes an
acute and neuropathic pain syndrome that limits its use. Among the mechanisms involved in …

Paclitaxel, a powerful anti-neoplastic drug, often causes pathological pain, which
significantly reduces the quality of life in patients. Paclitaxel-induced pain includes pain that …

Peripheral neuropathy is dose limiting in paclitaxel cancer chemotherapy and can result in
both acute pain during treatment and chronic persistent pain in cancer survivors. The …

Background Neuropathic pain is a common complication of treatment with the anti‐
neoplastic drug paclitaxel. Animal studies suggest neuroinflammation and transient receptor …